Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1986 1
1987 1
1991 2
1992 1
1993 2
1995 3
1996 2
1997 4
1998 4
1999 5
2000 2
2001 8
2002 7
2003 9
2004 2
2005 5
2006 6
2007 5
2008 4
2009 10
2010 6
2011 7
2012 10
2013 6
2014 6
2015 13
2016 14
2017 16
2018 14
2019 15
2020 14
2021 20
2022 15
2023 23
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Long palm"
Page 1
Dietary palmitic acid promotes a prometastatic memory via Schwann cells.
Pascual G, Domínguez D, Elosúa-Bayes M, Beckedorff F, Laudanna C, Bigas C, Douillet D, Greco C, Symeonidi A, Hernández I, Gil SR, Prats N, Bescós C, Shiekhattar R, Amit M, Heyn H, Shilatifard A, Benitah SA. Pascual G, et al. Nature. 2021 Nov;599(7885):485-490. doi: 10.1038/s41586-021-04075-0. Epub 2021 Nov 10. Nature. 2021. PMID: 34759321 Free article.
Both the PA-induced memory of this proneural signature and its long-term boost in metastasis require the transcription factor EGR2 and the glial-cell-stimulating peptide galanin. In summary, we provide evidence that a dietary metabolite induces stable transcriptional and c …
Both the PA-induced memory of this proneural signature and its long-term boost in metastasis require the transcription factor EGR2 an …
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K, Sutherland-Phillips D, Berni A, Latham CL, Zhang F, D'Amico R, Pascual Bernáldez M, Van Solingen-Ristea R, Van Eygen V, Patel P, Chounta V, Spreen WR, Garges HP, Smith K, van Wyk J. Ramgopal MN, et al. Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8. Lancet HIV. 2023. PMID: 37567205 Clinical Trial.
METHODS: SOLAR is a randomised, open-label, multicentre, phase 3b, non-inferiority study. ...Participants randomly assigned to long-acting therapy had a choice to receive cabotegravir (30 mg) plus rilpivirine (25 mg) once daily as an optional oral lead-in for …
METHODS: SOLAR is a randomised, open-label, multicentre, phase 3b, non-inferiority study. ...Participants randomly assigned to …
Alcohol Consumption and Cardiovascular Health.
Krittanawong C, Isath A, Rosenson RS, Khawaja M, Wang Z, Fogg SE, Virani SS, Qi L, Cao Y, Long MT, Tangney CC, Lavie CJ. Krittanawong C, et al. Am J Med. 2022 Oct;135(10):1213-1230.e3. doi: 10.1016/j.amjmed.2022.04.021. Epub 2022 May 14. Am J Med. 2022. PMID: 35580715 Free PMC article.
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
Llibre JM, Brites C, Cheng CY, Osiyemi O, Galera C, Hocqueloux L, Maggiolo F, Degen O, Taylor S, Blair E, Man C, Wynne B, Oyee J, Underwood M, Curtis L, Bontempo G, van Wyk J. Llibre JM, et al. Clin Infect Dis. 2023 Feb 18;76(4):720-729. doi: 10.1093/cid/ciac130. Clin Infect Dis. 2023. PMID: 35235656 Free PMC article. Clinical Trial.
BACKGROUND: In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-term noninferior efficacy vs continuing tenofovir alafenamide-based regimens in treatment-experienced adults with HIV-1. ...RESULTS: Overall, 493 adults (39% women; 39% aged 50 years; 19 …
BACKGROUND: In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-term noninferior efficacy vs continuing tenofo …
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-m …
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheime …
Percutaneous mechanical thrombectomy in a real-world pulmonary embolism population: Interim results of the FLASH registry.
Toma C, Bunte MC, Cho KH, Jaber WA, Chambers J, Stegman B, Gondi S, Leung DA, Savin M, Khandhar S, Kado H, Koenig G, Weinberg M, Beasley RE, Roberts J, Angel W, Sarosi MG, Qaqi O, Veerina K, Brown MA, Pollak JS. Toma C, et al. Catheter Cardiovasc Interv. 2022 Mar;99(4):1345-1355. doi: 10.1002/ccd.30091. Epub 2022 Feb 3. Catheter Cardiovasc Interv. 2022. PMID: 35114059 Free PMC article.
BACKGROUND: High- and intermediate-risk PEs are characterized by high mortality rates, frequent readmissions, and long-term sequelae. Mechanical thrombectomy is emerging as a front-line therapy for PE that enables immediate thrombus reduction while avoiding the bleeding ri …
BACKGROUND: High- and intermediate-risk PEs are characterized by high mortality rates, frequent readmissions, and long-term sequelae. …
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.
Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Tepper S, et al. Lancet Neurol. 2017 Jun;16(6):425-434. doi: 10.1016/S1474-4422(17)30083-2. Epub 2017 Apr 28. Lancet Neurol. 2017. PMID: 28460892 Clinical Trial.
We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in patients with chronic migraine. METHODS: This was a phase 2, randomised, double-blind, placebo-controlled, multicentre study of erenumab for adults aged 18-65 y …
We assessed the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in patients with chronic migra …
Effects of Chiropractic Care on Strength, Balance, and Endurance in Active-Duty U.S. Military Personnel with Low Back Pain: A Randomized Controlled Trial.
Vining R, Long CR, Minkalis A, Gudavalli MR, Xia T, Walter J, Coulter I, Goertz CM. Vining R, et al. J Altern Complement Med. 2020 Jul;26(7):592-601. doi: 10.1089/acm.2020.0107. Epub 2020 Jun 12. J Altern Complement Med. 2020. PMID: 32543211 Clinical Trial.
Objectives: To investigate whether chiropractic care influences strength, balance, and/or endurance in active-duty United States military personnel with low back pain (LBP). Design: This study employed a prospective randomized controlled trial using a pragmatic trea …
Objectives: To investigate whether chiropractic care influences strength, balance, and/or endurance in active-duty United States military pe …
After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy.
Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, Panzer U, Budde K, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JFE, Hilgers RD, Floege J; STOP-IgAN Investigators. Rauen T, et al. Kidney Int. 2020 Oct;98(4):1044-1052. doi: 10.1016/j.kint.2020.04.046. Epub 2020 May 22. Kidney Int. 2020. PMID: 32450154 Clinical Trial.
The randomized, controlled STOP-IgAN trial in patients with IgA nephropathy (IgAN) and substantial proteinuria showed no benefit of immunosuppression added on top of supportive care on renal function over three years. ...The primary endpoint was reached in 36 of 72 …
The randomized, controlled STOP-IgAN trial in patients with IgA nephropathy (IgAN) and substantial proteinuria showed no benef …
Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: A report of signal index cases and call for targeted research.
Scheppke KA, Pepe PE, Jui J, Crowe RP, Scheppke EK, Klimas NG, Marty AM. Scheppke KA, et al. Am J Emerg Med. 2024 Jan;75:122-127. doi: 10.1016/j.ajem.2023.09.051. Epub 2023 Oct 4. Am J Emerg Med. 2024. PMID: 37944296 Free article.
OBJECTIVE: Long COVID has afflicted tens of millions globally leaving many previously-healthy persons severely and indefinitely debilitated. ...Each rapidly returned to normal health and previous lifestyles/occupations with normalized exercise tolerance, still sustained to …
OBJECTIVE: Long COVID has afflicted tens of millions globally leaving many previously-healthy persons severely and indefinitely debil …
246 results